Immune response knowledge from FLAMINGO-01 reveals optimistic leads to sufferers with HER2+ breast most cancers, suggesting potential for additional therapy growth.
Therapy with the investigative agent GLSI-100 (GP2 plus GM-CSF) demonstrated an elevated immune response over time in sufferers with HER2-positive breast most cancers following surgical procedure, based on preliminary immune response knowledge from the section 3 FLAMINGO-01 trial.
Information from the trial, which had been shared in a information launch from a Greenwich LifeSciences Inc., confirmed that the investigative agent is creating an immune response over time. Notably, the therapy is creating seen pores and skin response on the injection website, which is a optimistic signal that their immune system is responding to the therapy. Furthermore, sufferers on each the HLA-A*02 (a genetic marker that helps the immune system acknowledge ailments) and non-HLA-A*02 arms skilled an immune response which elevated over time from baseline by means of the fourth to sixth month.
HLA-A*02 is a standard cell floor marker that’s a part of human leukocyte antigen (HLA) antigens, which decide an individual’s tissue kind. These antigens, discovered on most cells, play a key position within the physique’s immune response to international substances.
Extra findings from the trial observe that earlier than receiving the therapy, some sufferers already had an immune response to GP2, which is the important thing element of the investigative agent GLSI-100. This implies that previous most cancers remedies, like Herceptin (trastuzumab), could have helped the immune system acknowledge GP2.
The FLAMINGO-01 trial is designed to guage the security and efficacy of GLSI-100 in sufferers with HER2-positive breast most cancers who had residual illness or high-risk pathologic full response at surgical procedure and who’ve accomplished each neoadjuvant and postoperative adjuvant Herceptin-based therapy.
“We’re very inspired to see that the preliminary outcomes from FLAMINGO-01 present immune responses in each HLA-A*02 and non-HLA-A*02 sufferers,” CEO Snehal Patel mentioned within the information launch. “We are actually contemplating the deserves of including a randomized placebo arm for non-HLA-A*02 sufferers, reworking this present open-label third arm into successfully a second pivotal and blinded section 3 trial. If profitable, the Firm may pursue approval for each HLA-A*02 and non-HLA-A*02 sufferers in comparable time frames utilizing unbiased or mixed evaluation of the 2 affected person teams with the potential to double the marketplace for GP2 to as much as $10 billion in income per yr.”
Extra Data on the Investigation
Within the section 3 trial, roughly 500 HLA-A*02 sufferers are randomized to GLSI-100 or placebo, and as much as 250 sufferers of different HLA sorts will obtain GLSI-100 in a 3rd arm. As reported in a previous information launch, the non-HLA-A02 sorts which are mostly being enrolled in FLAMINGO-01 embody HLA-A*03, HLA-A*24, HLA-A*01, HLA-A*11, HLA-A*68, HLA-A*29, HLA-A*30, HLA-A*23 and HLA-A*33.
In the course of the potential, randomized, single-blinded, placebo-controlled section 2b scientific trial, 46 sufferers with HER2/neu 3+ over-expressor breast most cancers had been handled with GLSI-100, whereas 50 placebo sufferers acquired GM-CSF alone. After 5 years of follow-up, the HER2/neu 3+ sufferers handled with GLSI-100 confirmed an 80% or better discount in most cancers recurrences and remained disease-free in the course of the first six months, which is believed to be the time required to succeed in peak immunity and most efficacy.
HER2 (human epidermal progress issue receptor 2) is a cell floor protein expressed in varied cancers, together with 75% of breast cancers at low (1+), intermediate (2+) and excessive (3+ or over-expressor) ranges, based on the Nationwide Most cancers Institute.
“The Firm could select to broaden its immune response evaluation of GP2 particular T cells by sequencing the DNA of the T cells at baseline and after therapy with GP2, continued Patel within the information launch. “The T cell sequences could be in comparison with the immune response will increase over time. Growth into GP2-specific CAR-T cells may doubtlessly turn into one other platform expertise to enhance GP2 peptide therapy for non-responding higher-risk sufferers. Blood samples have been collected at a number of time factors for future T cell and immune response evaluation.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
